Targeting rare cancers with genomic therapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This open label, non-randomized, multi-center study aims to determine if patients with rare tumors can benefit from personalized molecular therapy based on their next-generation sequencing results. Participants will undergo comprehensive genomic profiling of their tumors and plasma DNA, with findings analyzed by a Virtual Molecular Tumor Board. The board will provide treatment recommendations to the treating physicians, who will make the final treatment decisions. The study allows for remote participation and traditional site-based enrollment across the United States.

Why it matters

Who can join: the full rules

INCLUSION CRITERIA

* Provision of signed and dated informed consent form.
* Stated willingness to comply with all study related blood draws and assessments for the duration of the study.
* Individuals who are 18 years old or older at the time of consent.
* Patients with a rare (fewer than 6 cases per 100,000 per year) solid tumor or lymphoma with evaluable disease at baseline. The complete list of included cancers are included in the study protocol; diseases not listed in the study protocol may be enrolled with the approval of the Principal Investigator.
* May or may not have had qualifying (by Foundation Medicine) comprehensive genomic profiling before the present study. For those who have had qualifying comprehensive genomic profiling performed prior to the present study, the archival specimen tested must have been harvested within 18 months of the baseline visit (i.e. date of consent) of the present study.
* Willingness to provide existing archived and/or newly collected tissue resulting from standard of care procedures and blood samples for genomic profiling. If the submitted sample is determined to be insufficient for testing, the patient will be considered to be a screen failure.
* For archival tissue to be used for comprehensive genomic profiling for the present study, that specimen must have been harvested within 18 months of the baseline visit (i.e. date of consent) of the present study.
* Willingness to provide clinical and medical information to the study team as required.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
* Ability to read, write and communicate in English.
* Ability to review and sign a web-based informed consent form, or review and sign an informed consent form in treating physician office.
* Resides within the United States.

EXCLUSION CRITERIA

* Participants who are unable to provide informed consent.
* Participants who are 17 years of age or younger.
* Participants who are unable to comply with the study procedures.
* Known existence of an uncontrolled intercurrent illness including, but not limited to, psychiatric illness or social situations that would impair compliance with study requirements.
* Concurrent active malignancy requiring treatment within 1 year of enrollment, at the discretion of treating physician.
* Pregnancy or breastfeeding.
* Any unlisted criteria at the discretion of the treating physician.

Where it's running

• TargetCancer Foundation
  Cambridge, Massachusetts, United States Recruiting

Study contacts

• Principal investigator: Razelle Kurzrock, M.D. — Medical College of Wisconsin
• Study coordinator: Mary Oster
• Email: track@targetcancer.org
• Phone: 617-299-0389

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SumMET: Targeted radioligand therapy for c-MET–positive solid tumors

  This first‑in‑human study tests the safety and potential effectiveness of a radioligand therapy called [225Ac]Ac-FL-261 in adults with advanced or metastatic solid tumors that overexpress c-MET.

  Recruiting at 2 sites Phase 1/2 Full-Life Technologies UK Limited · Minneapolis, Minnesota and 1 other locations · NCT07873450

• F520 with paclitaxel and carboplatin as first-line therapy for cancer of unknown primary

  This trial tests whether adding F520 to standard chemotherapy can improve responses in adults with cancer of unknown primary who have not yet received systemic therapy.

  Recruiting Phase 2/3 Shandong New Time Pharmaceutical Co., LTD · Shanghai, Shanghai Municipality · NCT07761429

• 68Ga-SorB PET/CT imaging for solid tumors

  This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.

  Recruiting Peking University Third Hospital · Beijing, Beijing Municipality · NCT07760012

• Breath test to help detect gastrointestinal cancers early

  A breath test that looks for signals in exhaled air to see if someone with gut cancer symptoms might have oesophageal, stomach, pancreatic, liver, or colorectal cancer and need urgent testing.

  Recruiting Imperial College London · Maidstone, Kent and 5 other locations · NCT07714538

• Can an imaging tracer help predict if cholangiocarcinoma patients will respond to standard therapy

  This study tests whether an imaging tracer called [18F]FTT used with PET/CT can predict how newly diagnosed cholangiocarcinoma patients will respond to the standard treatment of gemcitabine, cisplatin, and durvalumab.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT07673341

• Dual-target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer

  This trial tests a ready-to-use CAR-NK cell therapy that targets HER2 and CEACAM5 in adults with unresectable or metastatic biliary tract cancers after standard therapy to see if it can help control the disease.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07641036

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.